Myeloid or Lymphoid Neoplasms (MLN) clinical trials at UC Health

• Futibatinib in Patients With Specific FGFR Aberrations

  open to eligible people ages 18 years and up

  The purpose of this study is to evaluate the efficacy and safety of futibatinib in patients with FGFR aberrations in 3 distinct cohorts. Patients will be enrolled into one of 3 cohorts: patients with advanced, metastatic or locally-advanced solid tumors harboring FGFR1-4 rearrangements (excluding primary brain tumors and intrahepatic cholangiocarcinoma [iCCA]); patients with gastric or gastro-esophageal junction (GEJ) cancer harboring FGFR2 amplification; and patients with myeloid or lymphoid neoplasms with FGFR1 rearrangements.

  at UCLA

Last updated: November 9, 2020